Neurol. praxi. 2020;21(4):307-312 | DOI: 10.36290/neu.2020.089

Cryptogenic Neuropathy - a retrospective analysis - Transthyretin-related familial amyloid polyneuropathy - differential diagnostic pathway

MUDr. Jana Junkerová, MUDr. Eva Kovalová
Centrum pro diagnostiku a léčbu nervosvalových onemocnění, Neurologická klinika FN Ostrava, Lékařská fakulta OU, Ostrava

We retrospectively evaluated 2 years of our diagnostic efforts. The subjects of interest were 25 patients with acutely or subacutely progressing polyneuropathy, with the etiology remaining unclear in 22of cases even after the use of all available diagnostic methods. Transthyretin familial amyloid polyneuropathy, TTR-FAP, certainly belongs to the considerations of etiopathogenesis with a rare occurrence. Although we have not yet detected this diagnosis, we present a brief outline of the disease, reflections on the occurrence of this unit in our region and the possibilities of its diagnosis. We offer comparisons in the success of revealing the complex/unclear etiology of polyneuropathy and encourage a concerted effort to pay attention to systemic manifestations and find, for example, TTR-FAP.

Keywords: idiopathic, cryptogenic polyneuropathy, neuropathic syndrome with systemic manifestations, transthyretin amyloid polyneuropathy.

Received: June 16, 2020; Revised: August 21, 2020; Accepted: August 21, 2020; Prepublished online: August 21, 2020; Published: September 8, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Junkerová J, Kovalová E. Cryptogenic Neuropathy - a retrospective analysis - Transthyretin-related familial amyloid polyneuropathy - differential diagnostic pathway. Neurol. praxi. 2020;21(4):307-312. doi: 10.36290/neu.2020.089.
Download citation

References

  1. Adams D, Cauquil C, Labeyrie C. Familial amyloid polyneuropathy. Curr Opin Neurol 2017; 30: 1-9. Go to original source... Go to PubMed...
  2. Ando Y, Coelho T, Berk JL, Cruz mW, Ericzon BG, Ikeda SI, LewisWD, Obici L, Plánte-Bordeneuve V, rappezi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 8: 31. Cloi.10.1186/1750-1172-8-31. Go to original source... Go to PubMed...
  3. Andrade C. A peculiar form of peripheral neuropathy, familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427. Go to original source... Go to PubMed...
  4. Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013; 29: 63-67. Go to original source... Go to PubMed...
  5. Ericzon BG. Liver transplantation for TTR-FAP. In: Advances and Research on TTR Amyloidosis: Improving Diagnosis, Improving Outcomes. Barcelona 2013: 20-21.
  6. Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, Shibata-Hamaguchi A, Furukawa Y, Yanase D, Ishida C, et al. Epidemiology of familiar amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci 2008; 270: 133-140. Go to original source... Go to PubMed...
  7. Kubánek M, Buncová M, Honsová E. Transthyretinová kardiomyopatie - významná příčina srdečního selhání s novými možnoszmi diagnostiky a léčby. Interní Med. 2019; 21(2): 88-91. Go to original source...
  8. Kufová Z, Ševčíková S, Hájek R. Detekce hereditárních amyloidóz. Klin. Biochem. Metab. 2014; 22(43) No. 2: 65-69. Go to original source...
  9. Laštovičková J. Hereditární amyloidóza s defektem transthyretinu a její neurologické projevy. Neurol. praxi 2011; 12(2): 142-144.
  10. Merlini G, Belloti V. Molecular mechanism of amyloidosis. The New England Journal of Medicine. 2003; 349: 583-596. Go to original source... Go to PubMed...
  11. Maurer MS, Schwarz JH, Gundapaneni B. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 10007-1016. Go to original source... Go to PubMed...
  12. Paleček T, Krejčí J. Studie ATTR-ACT: přelom v léčbě transthyretinové srdeční amyloidózy. Interv Akut Kardiol 2019; 18(1): 45-48.
  13. Planté-Bordeneuve V, Suhr OB, Maurer MS, Grogan BWDR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013; 29: 77-84. Go to original source... Go to PubMed...
  14. Ruberg FL, Berk JL. Transthyretin TTR cardiac amyloidosis. Circulation 2012; 126(10): 1286-3000. Go to original source... Go to PubMed...
  15. Špalek P. Familiárna amyloidná polyneuropatia. Neurol.praxi 2013; 14(6): 296-300.
  16. Špalek P, Martinka I, Mattošová S, Cibulčík F, Chandoga J. Prvý prípad sporadickej late-onset formy transtyretínovej familiárnej polyneuropatie v SR. Neurol. prax 2019; 20(4).
  17. Špalek P, Skladaný L, Chandoga J, Cibulčík F. Familiárna amyloidná polyneuropatia - výskyt v SR, súčasné možnosti diagnostiky a aktuálne trendy v liečbe. Ces Slov Neurol Neurochir. 2012; 75(108): 524.
  18. Ueda M, Yamashita T, Misumi Y, Masuda T, AndoY. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan. Amyloid 2018; 25: 143-147. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.